Amerisourcebergen Corp ABC
We take great care to ensure that the data presented and summarized in this overview for AMERISOURCEBERGEN CORP is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ABC
View all-
Vanguard Group Inc Valley Forge, PA20.3MShares$3.77 Billion0.08% of portfolio
-
Black Rock Inc. New York, NY19.2MShares$3.55 Billion0.08% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD8.99MShares$1.66 Billion0.27% of portfolio
-
State Street Corp Boston, MA7.92MShares$1.47 Billion0.07% of portfolio
-
Wellington Management Group LLP Boston, MA5.02MShares$929 Million0.17% of portfolio
-
Jpmorgan Chase & CO New York, NY4.94MShares$914 Million0.08% of portfolio
-
Boston Partners Boston, MA4.12MShares$763 Million0.95% of portfolio
-
Geode Capital Management, LLC Boston, MA3.92MShares$726 Million0.07% of portfolio
-
Morgan Stanley New York, NY2.8MShares$519 Million0.04% of portfolio
-
Capital Research Global Investors Los Angeles, CA2.68MShares$496 Million0.12% of portfolio
Latest Institutional Activity in ABC
Top Purchases
Top Sells
About ABC
AmerisourceBergen Corporation sources and distributes pharmaceutical products in the United States and internationally. Its Pharmaceutical Distribution segment distributes brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to various healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers. It also provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; and packaging solutions to various institutional and retail healthcare providers. In addition, this segment distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; provides other services primarily to physicians who specialize in various disease states, primarily oncology, as well as to other healthcare providers, including hospitals and dialysis clinics; and offers data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers. The company's Other segment provides integrated manufacturer services, such as clinical trial support, product post-approval, and commercialization support; specialty transportation and logistics services for the biopharmaceutical industry; and sells pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and various other products to customers in the companion animal and production animal markets, as well as demand-creating sales force services to manufacturers. AmerisourceBergen Corporation was incorporated in 2001 and is headquartered in Conshohocken, Pennsylvania.
Insider Transactions at ABC
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
May 01
2024
|
Lauren M Tyler Director |
BUY
Grant, award, or other acquisition
|
Direct |
110
+6.17%
|
$25,190
$229.2 P/Share
|
May 01
2024
|
Dennis M Nally Director |
BUY
Grant, award, or other acquisition
|
Direct |
137
+1.13%
|
$31,373
$229.2 P/Share
|
May 01
2024
|
Werner Baumann Director |
BUY
Grant, award, or other acquisition
|
Direct |
110
+6.17%
|
$25,190
$229.2 P/Share
|
Apr 16
2024
|
Steven H Collis Chairman, President & CEO |
SELL
Open market or private sale
|
Direct |
10,754
-3.64%
|
$2,548,698
$237.48 P/Share
|
Apr 16
2024
|
Steven H Collis Chairman, President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,754
+3.51%
|
$957,106
$89.58 P/Share
|
Apr 15
2024
|
Robert P. Mauch Executive Vice President & COO |
SELL
Open market or private sale
|
Direct |
57,564
-70.22%
|
$13,527,540
$235.09 P/Share
|
Apr 15
2024
|
Robert P. Mauch Executive Vice President & COO |
BUY
Exercise of conversion of derivative security
|
Direct |
33,877
+29.24%
|
$3,015,053
$89.58 P/Share
|
Mar 19
2024
|
Steven H Collis Chairman, President & CEO |
SELL
Open market or private sale
|
Direct |
10,755
-3.64%
|
$2,581,200
$240.21 P/Share
|
Mar 19
2024
|
Steven H Collis Chairman, President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,755
+3.51%
|
$957,195
$89.58 P/Share
|
Mar 18
2024
|
Elizabeth S Campbell Executive Vice President |
SELL
Open market or private sale
|
Direct |
6,977
-45.83%
|
$1,660,526
$238.12 P/Share
|
Mar 12
2024
|
Lorence H. Kim Director |
BUY
Grant, award, or other acquisition
|
Direct |
843
+23.56%
|
-
|
Mar 12
2024
|
Richard W Gochnauer Director |
BUY
Grant, award, or other acquisition
|
Direct |
843
+2.85%
|
-
|
Mar 12
2024
|
Dermot Mark Durcan Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,053
+4.69%
|
-
|
Mar 12
2024
|
Dennis M Nally Director |
BUY
Grant, award, or other acquisition
|
Direct |
843
+6.66%
|
-
|
Mar 12
2024
|
Lon R Greenberg Director |
BUY
Grant, award, or other acquisition
|
Direct |
843
+3.02%
|
-
|
Mar 12
2024
|
Kathleen W Hyle Director |
BUY
Grant, award, or other acquisition
|
Direct |
843
+3.34%
|
-
|
Mar 12
2024
|
Redonda Miller Director |
BUY
Grant, award, or other acquisition
|
Direct |
843
+25.95%
|
-
|
Mar 12
2024
|
Werner Baumann Director |
BUY
Grant, award, or other acquisition
|
Direct |
843
+35.04%
|
-
|
Mar 12
2024
|
Lauren M Tyler Director |
BUY
Grant, award, or other acquisition
|
Direct |
843
+35.04%
|
-
|
Mar 11
2024
|
Richard W Gochnauer Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,593
+5.4%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 204K shares |
---|---|
Exercise of conversion of derivative security | 377K shares |
Bona fide gift | 5.6K shares |
---|---|
Payment of exercise price or tax liability | 157K shares |
Open market or private sale | 7.46M shares |